Inhibition of $\alpha v \beta 3$ integrin impairs adhesion and uptake of tumor-derived small extracellular vesicles

Wanessa Altei (✉ wanaltei@gmail.com)

Universidade Federal de Sao Carlos Centro de Ciencias Biologicas e da Saude <https://orcid.org/0000-0002-6636-7951>

Bianca Pachane

Universidade Federal de Sao Carlos Centro de Ciencias Biologicas e da Saude

Patty K. Santos

Universidade Federal de Sao Carlos Centro de Ciencias Biologicas e da Saude

Ligia Ribeiro

Universidade Estadual de Campinas

Bong Hwan Sung

Vanderbilt University

Alissa Weaver

Vanderbilt University

Heloisa Sobreiro Selistre de Araújo

Universidade Federal de Sao Carlos Centro de Ciencias Biologicas e da Saude

Research

Keywords: small extracellular vesicles, $\alpha v \beta 3$ integrin, adhesion, uptake, breast cancer

Posted Date: March 17th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-17483/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Extracellular vesicles (EVs) are lipid-bound particles that are naturally released from cells and mediate cell-cell communication. Integrin adhesion receptors are enriched in small EVs (SEVs) and SEV-carried integrins have been shown to promote cancer cell migration and to mediate organ-specific metastasis; however, how integrins mediate these effects is not entirely clear and could represent a combination of EV binding to extracellular matrix and cells.

Methods: To probe integrin role in EVs binding and uptake, we employed a disintegrin inhibitor (DisBa-01) of integrin binding with specificity for $\alpha v\beta 3$ integrin. EVs were purified from MDA-MB-231 cells conditioned media by serial centrifugation method. Isolated EVs were characterized by different techniques and further employed in adhesion, uptake and co-culture experiments.

Results: We find that SEVs secreted from MDA-MB-231 breast cancer cells carry $\alpha v\beta 3$ integrin and bind directly to fibronectin-coated plates, which is inhibited by DisBa-01. SEV coating on tissue culture plates also induces adhesion of MDA-MB-231 cells, which is inhibited by DisBa-01 treatment. Analysis of EV uptake and interchange between cells reveals that the amount of CD63-positive EVs delivered from malignant MDA-MB-231 breast cells to non-malignant MCF10A breast epithelial cells is reduced by DisBa-01 treatment. Inhibition of $\alpha v\beta 3$ integrin decreases CD63 expression in cancer cells suggesting an effect on SEV content.

Conclusion: In summary, our findings demonstrate for the first time a key role of $\alpha v\beta 3$ integrin in cell-cell communication through SEVs.

Background

During tumor progression, cancer cells and neighboring host cells interact with each other and with extracellular matrix (ECM) proteins including collagen, laminin, vitronectin, and fibronectin [1]. ECM influences cell polarity, migration, proliferation, differentiation and survival and its disorganization during cancer progression facilitates cellular transformation and metastasis and may contribute to drug resistance [2,3].

Cells are capable of transferring information to other cells and to the microenvironment via EVs [4,5]. EVs are membranous nanoparticles secreted from cells that carry a variety of bioactive molecular cargoes such as nucleic acids, proteins, and lipids [6–8]. EVs are currently classified into different subtypes according to their size, biogenesis mechanisms, cargoes, and so on [9]. They include larger EVs (LEVs) such as shed microvesicles (100-1,000 nm) from the cell membrane, [7] and SEVs which include exosomes (50 – 150 nm), secreted from endocytic pathways [10,11].

Integrins are critical adhesion receptors for ECM proteins that support cell adhesion and drive cell migration. For example, $\alpha 1\beta 1$ and $\alpha 2\beta 1$ integrins are major collagen receptors, whereas fibronectin binds preferentially to $\alpha 5\beta 1$ and $\alpha v\beta 3$ integrins. Amongst the particular sequences recognized by integrins, the

RGD (Arg-Gly-Asp) motif is found in many ECM proteins including vitronectin, fibronectin and laminin [12]. RGD is usually recognized by both $\alpha 5\beta 1$ and $\alpha v\beta 3$ integrins, however, these two integrins play divergent roles in cell adhesion and migration. Fibronectin adhesion by $\alpha 5\beta 1$ integrin results in highly dynamic thin cell protrusions in multiple directions while adhesion to $\alpha v\beta 3$ integrin results in a single large lamellipodium with more static adhesions at the leading edge [13–15]. In addition to the RGD motif, integrin and ECM conformations are crucial to their interaction indicating a complex mechanism [16,17].

During tumor development, expression levels of integrins changes in response to alterations on ECM (DeRita *et al.*, 2019). Integrin $\alpha v\beta 3$ is highly expressed in aggressive cancers, which is related to increase of tumor cell migration, adhesion and invasion during tumor progression [13,18–22]. Since integrin inhibition blocks cell migration, these receptors were considered a valuable target on cancer research [16,23–25]. However, cilengitide, a cyclic RGD-containing peptide that antagonizes $\alpha v\beta 3$ and $\alpha 5\beta 1$ integrins at nanomolar ranges had promising pre-clinical results but it was ineffective in phase I clinical outcomes [16].

As an alternative to RGD peptides, the disintegrins, a family of cysteine-rich peptides, present anti-migratory and anti-angiogenic effects in tumors with non-toxic properties [26,27]. Originally found in snake venom, most of disintegrins contain the adhesive RGD motif and are potent antagonists of $\alpha v\beta 3$ and $\alpha 5\beta 1$ integrins. DisBa-01 is a recombinant His-tag fusion RGD-disintegrin from *Bothrops alternatus* snake venom. Firstly recognized by its anti-platelet and anti-thrombotic effects [27,28], this protein also decreased migration speed and directionality of oral carcinoma cells. DisBa-1 is a selective nanomolar $\alpha v\beta 3$ integrin inhibitor [16,27]. We have demonstrated that DisBa-01 affinity for $\alpha v\beta 3$ integrin (K_d 4.63×10^{-7} M) is one hundred times higher than its affinity for $\alpha 5\beta 1$ integrin (K_d 7.62×10^{-5} M) [23], which makes this protein an excellent tool to study the roles of $\alpha v\beta 3$ integrin in the adhesion and migration processes [16,23,27,29].

Integrins carried on SEVs have been shown to supporting tumor spread and metastasis development [30–35]. Exosomes mediate cell adhesion to matrix components [36,37], In addition, $\alpha 5\beta 1$ integrin found on exosomes was shown to bind fibronectin and promote cancer cell adhesion and motility [38]. $\alpha v\beta 3$ integrin present on SEVs from PC3 and CWR22Pc prostate cancer cells induce migration of non-tumorigenic BHP-1 cells [35]. Moreover, *in vivo* studies showed the transfer of $\alpha v\beta 3$ integrin from SEVs to $\beta 3$ -negative recipient cells resulting in acquired ligand binding activity of the recipient cells [39]. In metastasis, integrins carried by exosomes from lung tropic models have been associated with organ site-specific metastasis, including $\alpha 6\beta 4$ and $\alpha v\beta 5$ which are associated with metastasis in lung and liver tissues respectively [32,40].

Despite the aforementioned data, the real contribution of EV-carried integrins to cellular communication in tumor development is still unclear. To better understand how $\alpha v\beta 3$ integrin receptor works in the context of EVs, we investigated the effect of integrin blocking on SEV adhesion and uptake by using the recombinant disintegrin DisBa-01. We show that DisBa-01 inhibits $\alpha v\beta 3$ integrin on isolated SEVs affecting their adhesion to purified ECM proteins and their uptake in recipient cells. Moreover, the

treatment of Dis*Ba*-01 to MDA-MB-231 cells expressing GFP-CD63 affect intracellular GFP-CD63 expression suggesting an effect on SEV cargo sorting. As far as we know, this is the first report of such roles for EV-carried α v β 3 integrin and further supports a key role for integrins in SEV recognition and uptake by recipient cells.

Methods

Cell lines and culturing

MDA-MB-231 (malignant) and MCF 10A (non-malignant) breast cell lines were purchased from ATCC and maintained in DMEM (Dulbecco's Modified Eagle Medium) and DMEM-F12 respectively. DMEM was supplemented with 10% fetal bovine serum (FBS) and DMEM-F12 was supplemented with 5% horse serum (HS). In experiments using SEVs, culture media were supplemented with SEV depleted serum (SEV⁻). To prepare FBS SEV⁻ and HS EV⁻, the sera were ultracentrifuged at 100,000 x g overnight, and the supernatant was collected. Cells were cultured at 37 °C in 5 % of CO₂ atmosphere. Cell number was counted using a TC20 automated cell counter (Bio-Rad, Hercules, CA, USA) with 0.4% trypan blue (Thermo Scientific, Waltham, MA, USA) prior experiments in order to check cell viability.

pLenti-GFP-CD63 plasmid, previously described by Hoshino et. al.[56], was used to make MDA-MB-231 cells stably expressing GFP-CD63. Human MDA-MB-231 cells (ATCC) and 293 FT packaging cells were grown in DMEM + 10% FBS. 293 FT cells transfection, viral harvest, and transduction of MDA-MB-231 cells were performed as previously described [57]. Transduced cells were selected with 4 µg/ml puromycin for 7 days.

Integrin inhibitor

Recombinant Dis*Ba*-01 was isolated from inclusion bodies of *E. coli* BL21(DE3)-pET28a-Dis*Ba*-01 culture and purified to homogeneity as previously described. [27] Purified disintegrin was labeled with Alexa Fluor 546 (Invitrogen) according to the manufacturer's instructions.

Isolation and purification of EVs from conditioned media

For EV isolation, 2.0×10^6 MDA-MB-231 cells were plated in T-150 flasks containing 15 mL culture media (total 10 flasks) and cultured for 48 h until reach 80% confluence. The culture media was replaced with 15 mL of Opti-MEM without serum and cells were further cultured for 48 h to obtain conditioned media. Conditioned media was submitted to serial centrifugation to respectively sediment live cells (300 x g for 10 min), dead cells (2,000 x g for 25 min), and large EVs (10,000 x g, Ti40 rotor for 30 min). The supernatant was concentrated to 30 ml volume in a concentrator (Sartorius, VS6041Cat# and 100 k MWCO), layered over 2 ml of 60% iodixanol in an ultracentrifuge tube (25 x 89 mm for SW 32 Ti rotor), and further centrifuged at 100,000 x g for 4 h. 3 ml was collected from the bottom of the tube and layered in a new centrifuge tube (40% iodixanol). Iodixanol solutions (20% wt/vol, 10% wt/vol, and 5% wt/vol) were layered over from the bottom to the top. Iodixanol solutions were prepared by diluting

OptiPrep (60% wt/vol aqueous iodixanol; Axis-Shield PoC) with 0.25 M sucrose/10 mM Tris, pH 7.5. The gradient was centrifuged at 100,000 x g for 18 h using a SW45 Ti rotor and 12 fractions of 1 ml each were collected. 2 ml of PBS was added to 1 ml fractions and ultracentrifuged in a tabletop centrifuge at 100,000 x g for 3 h using a TLA 100.3 rotor. Vesicles were resuspended in 50 mL PBS for subsequent studies.

Purified LEVs and SEVs were quantitated by Particle Metrix ZetaView PMX 110 and the protein amount was measured using microBCA.

We also uploaded all relevant data of our experiments to the EV-TRACK knowledgebase (EV-TRACK ID: EV190006) (Van Deun J, et al. *EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research*. Nature methods. 2017;14(3):228-32).

Characterization of purified EVs

Transmission electron microscopy: For negative staining of purified SEVs, 5 mL of EV samples was added to Formvar carbon film-coated grids (FCF-200-Cu; Electron Microscopy Sciences; Hatfield, PA) for 60 sec. Grids were immediately fixed with 4% paraformaldehyde in water for 20 min, stained with 2% uranyl acetate for 2 min, and allowed to air-dry. For each step, the excess of solution was removed by wicking with a filter paper. The grids were imaged using a TEM Tecnai F20 G2, 200Kv in 40000 x magnification.

Western blotting: Purified EVs were lysed with 1% SDS 50mM Tris pH 7.6-lysis solution, mixed with SDS sample buffer, and loaded onto 8% acrylamide gels (10 ml). Gels were transferred to nitrocellulose membranes and blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline with 0.05% Tween 20 (TBS-T) for 1-2 h. Membranes were probed with antibodies for EV markers, anti-CD63 (Abcam, ab59479), anti-Flotillin (BD, 610821), and anti-Alix (Sigma, SAB 4200476). As a negative control, anti-calnexin (Cell Signaling, mAb 2679) was used. Appropriate secondary antibodies were added and detected by ECL (Thermo Scientific, 32106 and 34095). The same procedure was applied to detect integrins and ECM proteins, fibronectin (Abcam, ab2413) and collagen (Abcam, ab34710).

Adhesion of isolated SEVs to different ECM proteins

A ninety-six well plates were coated with collagen (10 mg/ml) or fibronectin (2 mg/ml) overnight at 4 °C. For the experiment, isolated SEVs were labeled with ExoGlow (System Bioscience Uniscience) according to the manufacturer's instructions. Prior to incubation, vesicles were incubated with DisBa-01 in different concentrations (250, 500 and 1000 nM) in ice for 30 min and then plated (1.0×10^8 vesicles/well) over the coating for 4 h. After incubation, non-adherent SEVs were washed out and photomicrographs were acquired using a Nikon Plan Apo 60x/1.40 NA oil immersion lens in a Nikon Eclipse TE2000E microscope. For fluorescence intensity analysis, adhered green fluorescent vesicles were segmented from the background by thresholding and measured for integrated intensity using Image J Fiji (Analyze tab/Measure).

Cell adhesion on EV coating

Isolated small or large EVs were resuspended in PBS and added to a 96 well plate overnight (50 mg/ml). Prior to adhesion experiments, the wells were blocked with 1% BSA for 1 h. Fibronectin-coated wells (10 mg/ml) were used as a positive control of cell adhesion. 100 nM DisBa-01 was incubated on EV coating for 30 min. After washing unbound DisBa-01 using PBS, calcein-labeled MDA-MB-231 cells (5×10^6) were added and allowed to attach for 1 h. To measure adhesion, green fluorescence intensity was read in a SpectraMax I3 (Molecular Devices) plate reader.

SEV uptake by healthy breast cells

Uptake of purified SEVs: One day before the experiment, MCF 10A cells were plated in a 96 well plate in a density of 2.5×10^3 cells/well. Small EVs were labeled with ExoGlow kit (System Biosciences) and subsequently treated with DisBa-01 (100 or 1,000 nM). After treatment with the integrin inhibitor, 1.4×10^7 vesicles/well were added over the MCF 10A cells and allowed to internalize for 4 h. After incubation, the supernatant was removed and cells were washed. The uptake of ExoGlow-labeled SEVs was analyzed by epifluorescence microscopy in automated system ImageXpress Micro XLS (Molecular Devices) using a Nikon S Plan Fluor ELWD 40X /0.60 NA magnification lens.

Co-culture in transwell system: MCF10-A cells (1×10^3) were plated on glass coverslips inside a 24-well plate. After MCF 10A cells adhesion, transwell inserts with pore size of 0.4 mm were added to the wells. MDA-MB-231 cells expressing GFP-CD63 (1×10^4 , treated and non- treated with DisBa-01 at 1000 nM for 30 min prior incubation) were added to the transwell inserts and incubated for 6h. After incubation, MCF 10A cells were stained with DAPI and imaged in a Zeiss LSM 780 confocal microscope using a 63 X/1.3 NA objective lens.

To measure the vesicles in MCF 10A cells, the green fluorescence was quantitated by integrated intensity analysis. Percentage of inhibition was calculated by comparing the integrated intensity of green fluorescence in MCF 10A cells incubated with DisBa-01-treated MDA-MB-231 cells expressing GFP-CD63 to that incubated with DisBa-01-non-treated MDA-MB-231 cells expressing GFP-CD63.

Imaging for co-culture

Fluorescence microscopy: MCF 10A cells (1.5×10^5) were cultured on glass coverslips for 48 h. After adhesion, cells were labeled with Cell Tracker Red CMTPX according to manufacturer instructions (Invitrogen, C34552). MDA-MB-231 cells (1.0×10^6) labeled with Cell Trace CFSE (Life Technologies, C34554) according to manufacturer instructions or stably expressing GFP-CD63 were treated with 100 nM or 1,000 nM DisBa-01 for 30 min (untreated cells were used as a control), plated over an MCF 10A monolayer, and incubated for 24 h. Cells were fixed with 4% paraformaldehyde and stained with DAPI. Z-stack images were acquired in a Zeiss LSM 880 with Airyscan confocal microscope, using a 63x/1.40 Plan-APOCHROMAT oil lens and quantitated by integrated intensity using Fiji (Analyze tab/Measure). For extracellular SEV quantification, cell bodies were carefully selected and deleted from each image. GFP-

CD63 deposits surrounding cells were segmented from the background by thresholding and measured for area and integrated intensity using Fiji (Analyze tab/Measure).

Scanning electronic microscopy (SEM): MCF 10A cells (2.0×10^4) were plated in a Lab-Tek® chamber slide™ (LOBOV, Catalog Number: 177402) and incubated at 37 °C overnight. At the next day, MDA-MB-231 cells (DisBa-01-treated or non-treated) were plated at the same density over the MCF 10A cells and allowed to adhere for additional 24 h. Cells were then washed with PBS, fixed with 4% glutaraldehyde (Sigma-Aldrich®) for 1 h at 37 °C, and dehydrated by increasing ethanol concentration (50, 60, 70, 80, 90 and 100%, 10 min for each steps) before drying with hexamethyldisilazane (*Sigma-Aldrich*®). Cell morphology was characterized by scanning electronic microscopy (Inspect F50 - FEI®).

DisBa-01 uptake assay

DisBa-01 was labeled using Alexa Fluor® 546 dye (Invitrogen, Thermo Scientific) according to manufacturer's instructions. MDA-MB-231 expressing GFP-CD63 cells (1×10^4) were plated in 8-well Nunc™ Lab-Tek™ Chamber Slide (Thermo Scientific) and incubated overnight. At the next day, cells were incubated with DisBa-01 (1,000 nM) for 1 h and 4 h, fixed with 4% paraformaldehyde, and stained with DAPI. Slides were mounted with mounting media Prolong™ (Thermo Fisher Scientific). Confocal images were acquired in a Zeiss LSM 780 confocal microscope using a 63 X/1.3 NA objective lens. Zen software was used to acquire images and laser power was same for all conditions in order to compare the fluorescence intensity between different conditions.

Data analysis and statistics

At least three independent experiments were performed to acquire data for quantitation. All data sets were tested for normality using Shapiro-Wilk normality test in GraphPad Prism software. Mean $\pm$ standard error of the mean (SEM) were calculated and intergroup comparisons were made using One-way ANOVA or t Test (two-tailed paired or unpaired with Welch's correction) analysis. Values of $P < 0.05$ were considered statistically significant.

Results

Isolation, purification and characterization of SEVs from MDA-MB-231 cells

EVs were obtained from high-speed differential centrifugation of MDA-MB-231 cells conditioned medium. LEVs were collected by centrifugation at $10,000 \times g$ for 30 min. SEVs present on supernatant were concentrated onto a cushion of iodixanol and further purified by iodixanol density gradient ultracentrifugation [41]. Purified EVs were characterized by western blotting, particle size analysis and transmission electron microscopy (TEM) (Fig. 1). Nanoparticle tracking analysis (NTA) showed vesicles in the size range for typical SEVs with a peak at 110 nm and LEVs with peaks at 195, 345, and 405 nm (Fig. 1 a), consistent with previous descriptions [10]. SEV size and morphology were confirmed by TEM (Fig. 1 b). Western blot analysis identified SEVs in fractions 6 and 7 of the gradient enriched with the SEV

markers CD63, flotillin, and Alix, and LEVs positive for flotillin, while the negative control calnexin was detected only in the cell lysate (Fig. 1c). These data, together with NTA and TEM analysis, indicate that the purified SEVs preparation has typical characteristics of SEVs [7,42,43].

Purified SEVs bind to extracellular matrix proteins and support cell adhesion through avb3 integrin binding

Integrins carried by EVs should be displayed on the outside of the vesicles, competent to interact with ECM. To identify the ability of SEVs to adhere to ECM, purified SEVs were labeled with ExoGlow kit (System Biosciences) and added to tissue culture dishes coated with purified ECM components. We found that SEVs adhere to both collagen I (COL I)- and FN-coated plates (Fig. 2a). The presence of DisBa-01 in concentrations relevant to its affinity for avb3 integrin (250 – 1000 nM) inhibited SEV binding to FN, suggesting the presence of avb3 integrin on the surface of SEVs while only the highest DisBa-01 concentrations inhibited binding to COL I (Fig. 2a, b). Western blot analysis showed that $\alpha 5$, $\alpha 2$, αv , $\beta 1$, and $\beta 3$ integrin subunits are present in SEVs whereas LEVs contain only $\alpha 5$ and $\beta 1$ integrin subunits (Fig 2c). Notably, SEVs but not LEVs also had a significant amount of associated COL I and FN (Fig. 2c).

The presence of ECM components associated with SEVs suggested a mechanism by which SEVs may associate with cells, via ECM-integrin complexes that might interact with cellular integrin receptors [44]. To test this possibility, we performed cell adhesion experiments to EV-coated surfaces. Isolated SEVs or LEVs were used as substrates to support MDA-MB-231 cell adhesion (Fig. 2d). Calcein-labeled MDA-MB-231 cells showed higher adhesion to SEV-coated wells compared to non-coated wells. Cell adhesion to SEV coating was comparable with the positive FN-coated control, which could potentially be explained by the presence of FN or COL bound to integrin subunits on the SEVs. On the other hand, LEV coating did not support significant cell adhesion when compared with control (Fig. 2 d and e). In parallel, we treated cells and SEV/LEV coating with DisBa-01 (30 min incubation) to analyze the effect of integrin inhibition. Cell adhesion on SEV and fibronectin coating was significantly reduced by DisBa-01 treatment, which was not observed for LEV coating (Fig 2 f).

SEV uptake is inhibited by avb3 integrin blocking

An important question in the EV field is how are EVs recognized and taken up by recipient cells. On the basis of the adhesion data shown in Fig. 2, we performed immunofluorescence microscopy to investigate whether the interaction of EVs with recipient cells would be affected by DisBa-01. SEVs purified from MDA-MB-231 cells were labeled with carboxyfluorescein succinimidyl ester (CFSE), incubated with DisBa-01 in different concentrations for 30 min, and added to adherent non-tumorigenic MCF 10A breast epithelial cells. Epifluorescence microscopy revealed the presence of green fluorescent signals in MCF 10A cells suggesting the internalization of SEVs. On the other hand, treatment of SEVs with DisBa-01 (100 and 1000 nM) caused a significant reduction of this uptake (Fig. 3 a and b).

To identify whether avb3 integrin plays a role in SEV uptake, we stably expressed GFP-CD63 in MDA-MB-231 cells. A tetraspanin CD63 is an intrinsic membrane protein that is involved in exosome biogenesis

and detected only in the SEV fraction (Fig. 1c) being considered an exosome/SEV marker. [45] MDA-MB-231 cells expressing GFP-CD63 (donor cells) and MCF 10A cells (recipient cells) were respectively plated in the upper and lower wells of Transwell plates (Fig. 3d). GFP-CD63-enriched SEVs secreted from MDA-MB-231 cells were internalized into MCF 10A cells and the internalization was significantly reduced by DisBa-01 (Fig. 3c and e) suggesting that avb3 integrin has a key role in this uptake.

Integrin inhibition affects uptake of tumor SEVs by breast epithelial cells

Thus far our experiments show that adhesion and uptake of purified SEVs by MCF10A cells are reduced by DisBa-01 using the transwell co-culture system. To explore the role of avb3 integrin in the interchange of EVs between breast cancer and epithelial cells, MDA-MB-231 and MCF 10A cells were labeled with the cytoplasmic Cell Trace CFSE (Thermo Scientific) and Cell Tracker Red CMTPX (Thermo Scientific), respectively. After 24 h of co-culture, the transfer of vesicles from tumor cells to non-tumorigenic epithelial cells was clearly observed in the control condition by the presence of green signals in the red cells (Supp. Fig. 1). By contrast, we did not observe significant uptake of red signal by the green cells. However, delivery of vesicles to MCF10A cells was strongly reduced upon treatment for 24 hours with 1000 nM DisBa-01 (Supp. Fig. S2, a-b). To validate this finding, we used the GFP-CD63-expressing MDA-MB-231 cells in the adjacent coculture model and using confocal microscopy to validate that the SEVs were inside of recipient cells.

Analysis of scanning electron microscopy (SEM) confirmed the communication between tumor and non-tumorigenic cells (Fig. 4a, co-culture). DisBa-01 changed MDA-MB-231 cell morphology that was confirmed by circularity values of control and DisBa-01-treated cells (Fig. 4a, left column and b). In co-culture, the two different cell lines were connected to each other through either filopodia or retraction fibers and that connection was reduced by DisBa-01 (Fig. 4a, right column, zoom-in). Using fluorescence microscopy, we confirmed GFP-CD63-enriched vesicles are transferred through the connection observed in Fig. 4a (Fig. 4 c). MDA-MB-231-GFP-CD63 cells morphology was also affected by DisBa-01 (Fig. 4 d). Confocal microscopy revealed a significant reduction of GFP signal in MCF 10A cells after DisBa-01 treatment (Fig. 4e, f, and g; Supplementary Movie S1). Furthermore, extracellular deposition of GFP-CD63 was also reduced by DisBa-01 (Fig. 4h).

avb3 inhibition affects GFP-CD63 content on MDA-MB-231-GFP-CD63 cells

Considering the reduction of SEV uptake and extracellular CD63-GFP release by DisBa-01 shown in Fig. 4, we investigated whether the disintegrin could affect SEV content inside the tumor cells. For this purpose, Alexa Fluor 546-labeled DisBa-01 was incubated with MDA-MB-231 cells expressing GFP-CD63 for 1 h and 4 h. Evident reduction of CD63 signal was observed in the treated cells at the two incubation times (Fig. 5a and b). The disintegrin was detected inside the cells after 1 h treatment, and the signal was even stronger after 4h, indicating internalization of the protein. Furthermore, we observed that the greater the disintegrin signal, the smaller was the GFP signal, suggesting that DisBa-01 could be altering the endogenous SEV biogenesis or content. To confirm this effect, we demonstrated by western blotting of cell lysates that CD63 protein levels were reduced by treatment with DisBa-01, corroborating the results

obtained from confocal image analysis (Fig. 5c). Similarly, cellular levels of the exosome biogenesis-related protein Alix were also affected by disintegrin treatment (Fig. 5d). As extracellular CD63 deposition was reduced by this treatment (Fig 4g), these data suggest that DisBa-01 may induce degradation of several exosome biogenesis components in the endocytic system.

Discussion

During tumor progression, constant exchange of information between cancer cells and the surrounding microenvironment must occur to support tumor growth, vascularization and spreading. Extracellular vesicles cooperate with these processes by delivering information from malignant to non-malignant cells and to the ECM [46]. The avb3 integrin participates actively in tumor development and has been extensively studied as a target for anticancer therapy at a cellular level [47–50]. Here, we demonstrate the impact of avb3 inhibition on SEV adhesion and uptake by the disintegrin DisBa-01. Our results showed that SEVs bind to FN coated on tissue culture plates and their adhesion is significantly inhibited by DisBa-01. In addition, the avb3 integrin, that is a main target for DisBa-01, was identified on SEVs suggesting that this integrin is involved in interaction between SEVs and ECM proteins [51]. Consistent with that model, adhesion of MDA-MB-231 cells to tissue culture plates was promoted by SEV, but not by LEV coating, and inhibited by DisBa-01. Although cell attachment to LEV coating was not inhibited by DisBa-01, the avb3 integrin inhibitor diminished MDA-MB-231 cell attachment to SEV coating suggesting that SEV binds to cells in an integrin-dependent manner.

The horizontal transfer of exosomal avb3 integrin results in the propagation of integrin-associated phenotypes promoting cell migration and a migratory metastatic phenotype in many types of tumors [35,52–54]. Moreover, uptake of tumor-derived EVs promotes malignant alterations on recipient non-tumor cells [55]. We addressed the ability of DisBa-01 in reducing uptake of MDA-MB-231 cells-derived SEVs by MCF10A cells. As expected, the uptake of SEVs was significantly reduced suggesting an active participation of avb3 integrin in this route. Furthermore, we designed a new transwell co-culture system using MDA-MB-231 cells stably expressing GFP-CD63 and detected the reduction of GFP-CD63-enriched exosome uptake and internalization into MCF10A cells confirming the participation of avb3 integrin in exosomes in cell-cell communication.

Another co-culture experiment using two different cell types showed EV transfer from malignant cancer cells to non-malignant epithelial cells. Despite no phenotypic alterations were observed in non-malignant epithelial cells, avb3 integrin inhibition altered MDA-MB-231 cell morphology with reduced filopodia-like protrusions and reduced vesicle delivery. DisBa-01 treatment not only inhibited uptake of SEVs by recipient cells but also downregulated CD63 levels in donor cells reducing the number of vesicles delivered to the extracellular space. These data suggest that avb3 integrin is important for both SEV release and uptake. To the best of our knowledge, integrin regulation of EV biogenesis has not been reported yet. More in-depth investigations are necessary to understand how integrin inhibition affects the production and uptake of SEVs.

We propose a model of which DisBa-01 inhibits cell-cell communication by decreasing vesicle adhesion and transfer through binding to $\alpha\beta3$ integrin in SEVs (Fig. 4). The results shown here highlight the relevance of $\alpha\beta3$ integrin on a role of SEVs, which mediates cell-cell communication. Currently, there are no available pharmacological agents to modulate vesicular integrins from aggressive cancer cells.

Cancer cells can modify their environment by communicating with other cells through many mechanisms. Cancer cell EVs have been identified as a major way that cells communicate [5,6]. Mechanisms by which integrins in SEVs induce the interaction with recipient cells and how disintegrins inhibit this interaction are still unclear, however, our results show that integrin inhibition is more complex than expected and may be helpful in defining new targets for cancer treatment [16].

Conclusions

EVs are important players during tumor development supporting cell communication with the microenvironment and adjacent cells. Here we provide evidences that adhesion receptors, formerly studied only in a cellular level, are present on membrane of SEVs, thus being involved in processes such as EV adhesion and uptake.

Our findings show that inhibition of $\alpha\beta3$ integrin affects such processes, emphasizing the relevance of EV-carried integrins as a new target for cancer research. More in-depth research on the mechanisms should be addressed in future works.

Abbreviations

CANX – Calnexin

CFSE - Carboxyfluorescein succinimidyl ester

DMEM - Dulbecco's Modified Eagle Medium

ECM – Extracellular matrix

EVs – Extracellular vesicles

FBS – Fetal bovine serum

Flot – Flotilin

GFP – Green fluorescent protein

HS – Horse serum

K_d – Dissociation constant

LEVs – Large extracellular vesicles

NTA – Nanoparticle tracking analysis

RGD – Arginine - Glycine – Aspartate

SEM – Scanning electron microscopy

SEVs – Small extracellular vesicles

TEM – Transmission electron microscopy

WB – Western blotting

WCL – Whole cell lysate

Declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of supporting data

The authors declare that the data generated in the current study are available within the article or from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests. The work was funded in part by National Institute of Health [NIH grants: 1R01GM117916 and 1R01CA206458 to AMW].

Funding

This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo [FAPESP, 2013/00798-2, 2014/18747-8, 2016/22539-7] – Brazil, and National Institute of Health [NIH grants: 1R01GM117916 and 1R01CA206458 to AMW]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no competing financial interests.

Author contributions statement

Wanessa F. Altei is the responsible for the experiments and manuscript writing. Heloisa S. Selistre-de-Araújo made substantial contributions to the experimental design and revised the manuscript critically for important intellectual content. Alissa M. Weaver and Bong Hwan Sung also contributed to design of experiments and manuscript writing. Bianca C. Pachane contributed to adhesion and uptake experiments. Patty K. Santos performed western blotting experiments, and Ligia Nunes contributed to particle size analysis. All authors read and approved the final manuscript.

Acknowledgements

We thank the Laboratory of Molecular Biology of Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, which provided fluorescent confocal microscopic imaging services; The Group of Nanomedicine and Nanotoxicology of Instituto de Física de São Carlos, for particle size analysis services; Professor Regina Vincenzi Oliveira (Departamento de Química UFSCar) and Professor Otavio Henrique Thiemann (Instituto de Física de São Carlos), for the use of ultracentrifuges; The Laboratory of Structural Characterization (LCE/DEMa/UFSCar) for the microscopy facilities. We also thank for the technical support of Roberta Rosales on confocal images analysis, and Merlyn Emanuel for the scientific support. Finally, we thank FAPESP for the financial support.

References

1. Wong MS, Sidik SM, Mahmud R, Stanslas J. *Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. Clin Exp Pharmacol Physiol* [Internet]. 2013 May;40(5):307–19.
2. Crotti S, Piccoli M, Rizzolio F, Giordano A, Nitti D, Agostini M. *Extracellular Matrix and Colorectal Cancer: How Surrounding Microenvironment Affects Cancer Cell Behavior? J Cell Physiol* [Internet]. 2016 Oct 24;
3. Lu P, Weaver VM, Werb Z. *The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol.* 2012;196(4).
4. Minciacchi VR, Freeman MR, Di Vizio D. *Extracellular Vesicles in Cancer: Exosomes, Microvesicles and the Emerging Role of Large Oncosomes. Semin Cell Dev Biol* [Internet]. 2015 Apr;40:41–51.
5. Maia J, Caja S, Strano Moraes MC, Couto N, Costa-Silva B. *Exosome-based cell-cell communication in the tumor microenvironment. Front Cell Dev Biol.* 2018;6(FEB):1–19.
6. Sato S, Weaver AM. *Extracellular vesicles: Important collaborators in cancer progression. Essays Biochem.* 2018;62(2):149–63.
7. van Niel G, D'Angelo G, Raposo G. *Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol* [Internet]. 2018;
8. Walker S, Busatto S, Pham A, Tian M, Suh A, et al. *Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics.* 2019;9(26):8001–17.

9. Zebrowska A, Skowronek A, Wojakowska A, Widlak P, Pietrowska M. *Metabolome of exosomes: Focus on vesicles released by cancer cells and present in human body fluids. Int J Mol Sci.* 2019;20(14).
10. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, et al. *Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A [Internet].* 2016 Feb 23;113(8):E968-77.
11. Junker K, Heinzelmann J, Beckham C, Ochiya T, Jenster G. *Extracellular Vesicles and Their Role in Urologic Malignancies. Eur Urol [Internet].* 2016 Aug 1;70(2):323–31.
12. Nieberler M, Reuning U, Reichart F, Notni J, Wester H-J, et al. *Exploring the Role of RGD-Recognizing Integrins in Cancer. Cancers (Basel) [Internet].* 2017 Sep 4;9(12):116.
13. Roca-Cusachs P, Gauthier NC, del Rio A, Sheetz MP. *Clustering of $\alpha 5 \beta 1$ integrins determines adhesion strength whereas $\alpha v \beta 3$ and talin enable mechanotransduction. Proc Natl Acad Sci [Internet].* 2009 Sep 22;106(38):16245–50.
14. Bachmann M, Schäfer M, Weißenbruch K, Mykuliak V, Heiser L, et al. *Force-dependent ligand sensing enables $\alpha v \beta 3$ integrin to differentiate between fibronectin and high-affinity ligands. DoiOrg [Internet].* 2017;200493.
15. Montenegro CF, Casali BC, Lino RLB, Pachane BC, Santos PK, et al. *Inhibition of $\alpha v \beta 3$ integrin induces loss of cell directionality of oral squamous carcinoma cells (OSCC). Languino LR, editor. PLoS One [Internet].* 2017 Apr 24;12(4):e0176226.
16. Altei WF, Selistre-de-araujo HS. *Integrin Inhibition in the Tumor Microenvironment – more complex than expected.* 2018;3(2):1–6.
17. Bretsch M, Cheng C, Witt H, Dimitrakopoulou-Strauss A, Strauss LG, et al. *Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ^{18}F -FDG PET and gene expression analysis. J Cancer Res Clin Oncol [Internet].* 2013 Apr;139(4):573–83.
18. PÉCHEUR I, PEYRUCHAUD O, SERRE C-M, GUGLIELMI J, VOLAND C, et al. *Integrin $\alpha v \beta 3$ expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J [Internet].* 2002 Aug;16(10):1266–8.
19. Truong H, Danen EHJ. *Integrin switching modulates adhesion dynamics and cell migration. Cell Adh Migr [Internet].* 2009;3(2):179–81.
20. De Franceschi N, Hamidi H, Alanko J, Sahgal P, Ivaska J. *Integrin traffic - the update. J Cell Sci [Internet].* 2015 Mar 1;128(5):839–52.
21. Haeger A, Alexander S, Vullings M, Kaiser FMP, Veelken C, et al. *Collective cancer invasion forms an integrin-dependent radioresistant niche. J Exp Med.* 2020;217(1):1–18.
22. Attieh Y, Clark AG, Grass C, Richon S, Pocard M, et al. *Cancer-associated fibroblasts lead tumor invasion through integrin- $\beta 3$ -dependent fibronectin asse. J Cell Biol.* 2017;216(11):3509–20.

23. Montenegro CF, Casali BC, Lino RLB, Pachane BC, Santos PK, et al. *Inhibition of $\alpha v \beta 3$ integrin induces loss of cell directionality of oral squamous carcinoma cells (OSCC)*. Languino LR, editor. *PLoS One* [Internet]. 2017 Apr 24;12(4):e0176226.
24. Urrea F, Araya-Maturana R, Urrea FA, Araya-Maturana R. *Targeting Metastasis with Snake Toxins: Molecular Mechanisms*. *Toxins (Basel)* [Internet]. 2017 Nov 30;9(12):390.
25. Sheu JR, Yen MH, Kan YC, Hung WC, Chang PT, Luk HN. *Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of trifluvin, an Arg-Gly-Asp-containing peptide and anti- $\alpha(v)\beta 3$ integrin monoclonal antibody*. *Biochim Biophys Acta*. 1997;1336:445–54.
26. Barja-Fidalgo C, Coelho ALJ, Saldanha-Gama R, Helal-Neto E, Mariano-Oliveira A, de Freitas MS. *Disintegrins: Integrin selective ligands which activate integrin-coupled signaling and modulate leukocyte functions*. *Brazilian J Med Biol Res*. 2005;38(10):1513–20.
27. Ramos OHP, Kauskot A, Cominetti MR, Bechyne I, Salla Pontes CL, et al. *A novel $\alpha v \beta 3$ -blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis*. *Clin Exp Metastasis*. 2008;25(1):53–64.
28. Kauskot A, Cominetti MR, Ramos OHP, Bechyne I, Renard J-M, et al. *Hemostatic effects of recombinant DisBa-01, a disintegrin from Bothrops alternatus*. *Front Biosci*. 2008;13:6604–16.
29. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, et al. *Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines*. *J Extracell Vesicles* [Internet]. 2018 Dec 23;7(1):1535750.
30. Jimenez L, Yu H, McKenzie AJ, Franklin JL, Patton JG, et al. *Quantitative Proteomic Analysis of Small and Large Extracellular Vesicles (EVs) Reveals Enrichment of Adhesion Proteins in Small EVs*. *J Proteome Res* [Internet]. 2019 Mar 4;18(3):947–59.
31. DeRita RM, Sayeed A, Garcia V, Krishn SR, Shields CD, et al. *Tumor-Derived Extracellular Vesicles Require $\beta 1$ Integrins to Promote Anchorage-Independent Growth*. *iScience* [Internet]. 2019;14:199–209.
32. Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, et al. *Tumour exosome integrins determine organotropic metastasis*. *Nature* [Internet]. 2015;527(7578):329–35.
33. Paolillo M, Schinelli S. *Integrins and Exosomes, a Dangerous Liaison in Cancer Progression*. *Cancers (Basel)* [Internet]. 2017 Jul 26;9(8).
34. Longmate W, DiPersio CM. *Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment*. *F1000Research* [Internet]. 2017 Aug 31;6:1612.
35. Singh A, Fedele C, Lu H, Nevalainen MT, Keen JH, Languino LR. *Exosome-Mediated Transfer of $\alpha v \beta 3$ Integrin from Tumorigenic to Non-Tumorigenic Cells Promotes a Migratory Phenotype*. *Mol Cancer Res* [Internet]. 2016;14(November):1136–46.
36. Koumangoye RB, Sakwe AM, Goodwin JS, Patel T, Ochieng J. *Detachment of Breast Tumor Cells Induces Rapid Secretion of Exosomes Which Subsequently Mediate Cellular Adhesion and Spreading*. Srivastava RK, editor. *PLoS One* [Internet]. 2011 Sep 6;6(9):e24234.

37. Ochieng J, Pratap S, Khatua AK, Sakwe AM. *Anchorage-independent growth of breast carcinoma cells is mediated by serum exosomes*. *Exp Cell Res* [Internet]. 2009 Jul 1;315(11):1875–88.
38. Sung BH, Ketova T, Hoshino D, Zijlstra A, Weaver AM. *Directional cell movement through tissues is controlled by exosome secretion*. *Nat Commun* [Internet]. 2015;6(May):7164.
39. Krishn SR, Singh A, Bowler N, Duffy AN, Friedman A, et al. *Prostate cancer sheds the $\alpha v\beta 3$ integrin in vivo through exosomes*. *Matrix Biol* [Internet]. 2019 Apr;77:41–57.
40. Weidle UH, Birzele F, Kollmorgen G, Rüger R. *The Multiple Roles of Exosomes in Metastasis*. *Cancer Genomics Proteomics* [Internet]. 2017;14(1):1–15.
41. Li K, Wong DK, Hong KY, Raffai RL. *Cushioned–Density Gradient Ultracentrifugation (C-DGUC): A Refined and High Performance Method for the Isolation, Characterization, and Use of Exosomes*. In: *Methods in molecular biology* (Clifton, NJ) [Internet]. 2018: p. 69–83.
42. Zhang H-G, Grizzle WE. *Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions*. *Am J Pathol* [Internet]. 2014 Jan;184(1):28–41.
43. Mathivanan S, Ji H, Simpson RJ. *Exosomes: extracellular organelles important in intercellular communication*. *J Proteomics* [Internet]. 2010 Sep 10;73(10):1907–20.
44. Sung BH, Ketova T, Hoshino D, Zijlstra A, Weaver AM. *Directional cell movement through tissues is controlled by exosome secretion*. *Nat Commun* [Internet]. 2015;6(May):1–14.
45. Sung BH, Pelletier R, Weaver AM. *pHluo_M153R-CD63, a bright, versatile live cell reporter of exosome secretion and uptake, reveals pathfinding behavior of migrating cells*. *bioRxiv* [Internet]. 2019 Mar 14;577346.
46. Mu W, Rana S, Zöller M. *Host matrix modulation by tumor exosomes promotes motility and invasiveness*. *Neoplasia* [Internet]. 2013;15(8):875–87.
47. Tolomelli A, Galletti P, Baiula M, Giacomini D, Tolomelli A, et al. *Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators*. *Cancers (Basel)* [Internet]. 2017 Jul 5;9(12):78.
48. Mas-moruno C, Rechenmacher F, Kessler H. *Cilengitide: The First Anti-Angiogenic Design , Synthesis and Clinical Evaluation Molecule Drug*. 2010;753–68.
49. Marinelli L, Lavecchia A, Gottschalk KE, Novellino E, Kessler H. *Docking studies on $\alpha(v)\beta(3)$ integrin ligands: Pharmacophore refinement and implications for drug design*. *J Med Chem*. 2003;46(21):4393–404.
50. Calvete JJ, Paz Moreno-Murciano M, David R, Theakston G, Kisiel DG, Marcinkiewicz C. *Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering*. Vol. 372, *Biochem. J*. 2003.
51. Attieh Y, Clark AG, Grass C, Richon S, Pocard M, et al. *Cancer-associated fibroblasts lead tumor invasion through integrin- $\beta 3$ –dependent fibronectin assembly*. *J Cell Biol* [Internet]. 2017;216(11):jcb.201702033.

52. Fedele C, Singh A, Zerlanko BJ, Iozzo R V, Languino LR. *The $\alpha(v)\beta(3)$ integrin is transferred intercellularly via exosomes.* *J Biol Chem.* 2015;290(8):4545–51.
53. Zhang L, Yu D. *Exosomes in cancer development, metastasis, and immunity.* *Biochim Biophys Acta - Rev Cancer* [Internet]. 2019;1871(2):455–68.
54. Wortzel I, Dror S, Kenific CM, Lyden D. *Exosome-Mediated Metastasis: Communication from a Distance.* *Dev Cell* [Internet]. 2019;49(3):347–60.
55. Singh A, Fedele C, Lu H, Nevalainen MT, Keen JH, Languino LR. *Exosome-mediated transfer of $\alpha v\beta 3$ integrin from tumorigenic to nontumorigenic cells promotes a migratory phenotype.* *Mol Cancer Res.* 2016;14(11):1136–46.
56. Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, et al. *Exosome secretion is enhanced by invadopodia and drives invasive behavior.* *Cell Rep* [Internet]. 2013 Dec 12;5(5):1159–68.
57. Bryce NS, Clark ES, Leysath JL, Currie JD, Webb DJ, Weaver AM. *Cortactin promotes cell motility by enhancing lamellipodial persistence.* *Curr Biol* [Internet]. 2005 Jul 26;15(14):1276–85.

Figures

Figure 1

Validation of cancer cell-derived EV isolation and characterization. (a) Representative trace and video acquisition snapshot from nanoparticle tracking analysis of small and large EVs. Both traces show vesicles within typical size profile. (b) Transmission electron microscopy of density gradient-purified SEVs and LEVs. Yellow arrows point to representative EVs. Scale bar: 500 nm (large image) and 100 nm (zoomed images). (c) WB for the EV markers CD63, Flotillin and Alix across 12 iodixanol density gradient fractions, large vesicles (LEV) and whole cell lysate (WCL) of the EV donor cells. Calnexin (CANX) antibody was used as a negative control.

Figure 2

SEVs adhere to ECM components and support MDA-MB-231 cell adhesion. (a) Representative epifluorescence images of CFSE-labeled-SEV adhesion to fibronectin and collagen coating. Treated (DisBa-01 500 nM) and untreated (CTRL) groups are compared. Scale bar: 100 μ m (whole images); 10 μ m (zoomed images). (b) Quantitation of SEV adhesion to fibronectin and collagen. **** $P < 0.0001$ * $P < 0.05$. (c) Western blot analysis of integrin subunits, $\alpha 5$, $\alpha 1$, $\alpha 2$, $\alpha 3$, and αv and ECM proteins, FN and COL on isolated SEVs and LEVs. (d) Schematic cartoon of cell adhesion assay to EV coating. (e) Representative images of Calcein AM-labeled MDA cell adhesion to well bottom, SEVs LEV and FN coating comparing cell adhesion in control (CTRL) and DisBa-01 (100 nM) treated conditions. (f) Calcein AM fluorescence intensity of adherent cells. Comparison of adhesion in different coating and effect of DisBa-01 at 100 nM. *, groups compared with the non-coated BSA blocked control. $p < 0.05$; *** $p < 0.001$ **** $p < 0.0001$;

Figure 3

Inhibition of SEV uptake by $\alpha v \beta 3$ integrin blocking. (a) Representative images of SEV uptake in MCF 10A cells. Arrows indicate internalized SEVs. Ctrl, control. Scale bar, 50 μ m. (b) Integrated intensity of CFSE-labeled SEV internalized in MCF 10A cells **** $P < 0.0001$. (c) Representative images of MDA-MB-231 cells-derived GFP-CD63 uptake in MCF 10A cells. Arrows indicate internalized GFP-CD63. Ctrl, control. Scale bar, 10 μ m. D) Schematic view of transwell system; (e) Quantitation of relative uptake of vesicles **** $P < 0.0001$.

Figure 4

DisBa-01 inhibits SEV uptake in a co-culture system. (a) Scanning electron microscopy of MDA-MB-231 and MCF 10A cells in single and co-culture systems. Ctrl, control. DisBa-01, 1000 nM. Scale bar, 10 μ m. (b) Effect of integrin inhibition on MDA-MB-231 cell morphology. ** $P < 0.01$. (c) Representative epifluorescence images highlighting distribution of GFP-CD63-enriched vesicles between MDA-MB-231 expressing GFP-CD63 (green) and MCF10 A (red) cells. Scale bar, 50 μ m. (d) Effect of integrin inhibition

on MDA-MB-231-GFP-CD63 cell morphology. *** $P < 0.001$. (e) Extracellular GFP-CD63-EVs from tumor to non-malignant cells. Z-stack slices from confocal acquisition show reduction of internalized and extracellular SEVs in DisBa-01 treated cells. (f) Orthogonal view of MCF 10A cells showing internalized GFP-CD63-SEVs and their reduction upon DisBa-01 treatment. (g) Effect of integrin inhibition on SEV uptake. *** $P < 0.001$. h) Effect of integrin inhibition on extracellular GFP-CD63. **** $P < 0.001$.

Figure 5

DisBa-01 decreases GFP-CD63 content. (a) Stacks from confocal images showing reduction of GFP-CD63 intensity 1h and 4h after DisBa-01 treatment. CTRL, control. (b) Quantitation of green fluorescent

signal of GFP-CD63. Reduced expression level of CD63 (c) and Alix (d) after treatment with DisBa-01 in western blotting analysis. **P < 0.01, ***P < 0.001, ****P < 0.0001. Scale bar, 10 μm.

Figure 6

Proposed model for inhibition of SEV adhesion and cellular uptake by recipient cells upon blockage of $\alpha v \beta 3$ integrin. (a) In the absence of DisBa-01, tumor cells secrete SEVs that bind to ECM and are taken by non-malignant cells. (b) Blocking $\alpha v \beta 3$ integrin by DisBa-01 decreases SEV secretion, adhesion to ECM proteins and uptake by recipient cells.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supp.zip](#)